The role of DNMT3A mutations in clonal heterogeneity and evolution of hematopoiesis
DNMT3A 突变在克隆异质性和造血进化中的作用
基本信息
- 批准号:10398064
- 负责人:
- 金额:$ 34.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-15 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:ATAC-seqAcute Myelocytic LeukemiaAddressAgeAge-YearsAgingAnimalsArchitectureAutomobile DrivingBiological AssayBloodBlood CellsBone MarrowBone Marrow CellsCardiovascular DiseasesCell Fate ControlCell SeparationCell SurvivalCellsCellular AssayChromatinChromatin StructureClonal EvolutionClone CellsColorComplementComplexDNADNA DamageDNA MethylationDNA Modification MethylasesDNA Modification ProcessDNA Sequence AlterationDNA analysisDNMT3aDNMT3a mutationDataDiseaseDysmyelopoietic SyndromesEpigenetic ProcessEventEvolutionFluorescence-Activated Cell SortingFrequenciesGene ExpressionGene Expression ProfilingGenesGeneticGenetic TranscriptionHematopoiesisHematopoieticHematopoietic SystemHematopoietic stem cellsHeterogeneityHuman GeneticsIn VitroIndividualKnock-in MouseKnowledgeLeadLeukemic Hematopoietic Stem CellLiteratureLongevityMapsMarrowMasksMeasuresMethodsModelingMolecularMutationMyeloproliferative diseaseNon-Hematologic MalignancyNucleosomesPathway interactionsPeriodicityPersonsPhenotypePopulationPositioning AttributePrecancerous ConditionsProcessRelaxationReportingResolutionRoleSamplingSignal PathwaySignal TransductionSourceStressStretchingSystemTechniquesTechnologyTimeTobacco smokeWorkage relatedbisulfite sequencingcancer therapycardiovascular risk factorchemotherapychromatin remodelingepigenomeepigenomicsfitnessgenetic profilinggenetic variantgenotoxicityhematopoietic stem cell fatehematopoietic stem cell quiescencein vivoleukemiamouse modelmutantpremalignantpressurepreventprospectiverational designself-renewalsingle moleculestemstem cell fatestem cellstemporal measurementtherapeutic targettranscription factortranscriptome sequencingtranscriptomics
项目摘要
ABSTRACT
Clonal hematopoiesis, frequently found in people over 70 years of age, occurs when a single hematopoietic
stem/progenitor cell dominates all other stem cells in the bone marrow and yields a large fraction of all
differentiated blood cells, and may aggravate coincident cardiovascular disease or progress to myeloid
malignancy. Accumulation of genetic and epigenetic variability permits the cells to sample a diverse set of gene
expression states allowing selection of hematopoietic clones with the highest fitness, especially after genotoxic
exposures such as tobacco smoke or prior cancer therapy. Mutations in epigenetic modifiers such as DNMT3A
are ancestral events occurring in age-related clonal hematopoiesis, and are enriched in pre-leukemic and
leukemic HSCs that persist following chemotherapy. Preliminary studies in Dnmt3a-mutant knock-in mice that
we developed show substantial functional variability among Dnmt3a-mutant hematopoietic clones compared to
controls. Conventional ensemble methods mask cell-to-cell heterogeneity due to population averaging, while
single-cell techniques are not amenable to prospective isolation of cells for functional assays. We developed an
in vivo multicolor clonal tracking system, allowing easy characterization of clonal composition in the
bone marrow over the lifespan of an animal, enabling capture of clonal evolution at unprecedented temporal
resolution. Importantly, this system is suitable for isolation of individual hematopoietic clones by
fluorescence-activated cell sorting, enabling functional and –omics analyses. In this proposal, we track clonal
architecture and emergence of dominant clones in vivo in real time, in steady-state and under selective
pressures, and evaluate the contribution of specific genetic backgrounds such as presence of Dnmt3a mutations
into this process. Next, we isolate dominant (“winners”) and non-dominant (“losers”) clones and perform
transcriptomic, epigenomic, and chromatin profiling analyses, to investigate specific pathways and epigenetic
state(s) driving clonal dominance. This will be done using conventional ensemble methods in FACS-sorted
dominant clones (RNA-seq, DNA bisulfite sequencing, ATAC-seq), and complemented by MAPit technology
allowing simultaneous analysis of DNA methylation and nucleosome positioning over long stretches of single
molecules of DNA, to add granularity to the epigenome heterogeneity studies. These results are cross-validated
by functional long-term self-renewal assays ex vivo in isolated dominant and non-dominant bone marrow cells,
and by single-cell transcriptomic analysis. These findings will deepen our understanding of clonal evolution in
the hematopoietic system. More importantly, the results of our studies will generate a rich source of potential
therapeutic targets to hinder or prevent the progression to pre-malignant states and to frank leukemia.
!
摘要
克隆性造血,常见于70岁以上的人,当一种单一的造血细胞
干细胞/祖细胞支配着骨髓中的所有其他干细胞,并产生ALL的很大一部分
分化的血细胞,并可能加重同时发生的心血管疾病或进展为髓系
恶毒。遗传和表观遗传变异性的积累允许细胞对一组不同的基因进行采样
表达状态允许选择具有最高适合度的造血细胞克隆,特别是在基因毒性之后
暴露于烟草烟雾或以前的癌症治疗。DNMT3A等表观遗传修饰因子的突变
是发生在与年龄相关的克隆性造血中的祖先事件,并在白血病前期和
化疗后持续存在的白血病HSCs。DNMT3A基因敲除突变小鼠的初步研究
我们发现在DNMT3A突变的造血克隆中,与
控制。传统的集成方法由于总体平均而掩盖了细胞到细胞的异质性,而
单细胞技术不适合用于功能分析的预期细胞分离。我们开发了一种
体内多色克隆跟踪系统,允许轻松表征克隆成分
在动物的整个生命周期中的骨髓,使得能够在前所未有的时间捕捉克隆进化
决议。重要的是,该系统适用于通过以下方式分离单个造血克隆
荧光激活的细胞分类,实现功能和组学分析。在这个提案中,我们跟踪克隆
在活体中实时、稳定和选择性地构建和出现优势克隆
压力,并评估特定遗传背景的贡献,如DNMT3A突变的存在
进入这一过程。接下来,我们分离优势克隆(“赢家”)和非优势克隆(“输家”)并执行
转录、表观基因组和染色质图谱分析,以研究特定的途径和表观遗传学
状态(S)驱动克隆显性。这将在FACS中使用传统的集成方法来完成-分类
优势克隆(RNA-SEQ、DNA亚硫酸氢盐测序、ATAC-SEQ),并由MapIt技术补充
允许同时分析DNA甲基化和核小体定位
DNA分子,以增加表观基因组异质性研究的粒度。这些结果是交叉验证的
通过在分离的优势和非优势骨髓细胞中进行体外功能长期自我更新试验,
并进行单细胞转录分析。这些发现将加深我们对克隆进化的理解
造血系统。更重要的是,我们的研究成果将产生丰富的潜力来源
治疗靶点,以阻止或防止进展到癌前状态和坦率的白血病。
好了!
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Olga A Guryanova其他文献
NPM1 Mutation Reprograms Leukemic Transcription Network Via Reshaping CTCF-Defined TAD Topology
- DOI:
10.1182/blood-2022-160367 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:
- 作者:
Karina Hamamoto;Qian Lai;Huacheng Luo;Julia Lesperance;Zachary Zaroogian;Jie Zha;Yi Qiu;Olga A Guryanova;Bing Xu;Suming Huang - 通讯作者:
Suming Huang
3015 – CLONAL HEMATOPOIESIS DRIVEN BY PARTIAL DNMT3A LOSS CONTRIBUTES TO AN AGGRESSIVE PHENOTYPE OF COLITIS-ASSOCIATED COLON CANCER
- DOI:
10.1016/j.exphem.2021.12.237 - 发表时间:
2021-08-01 - 期刊:
- 影响因子:
- 作者:
Olga A Guryanova;Yang Feng;Rachel Newsome;Troy Robinson;Robert Bowman;Ashley Zuniga;Kendra Hall;Cassandra Berntsen;Daniil Shabashvili;Ross Levine;Alberto Riva;Christian Jobin;Dorina Avram - 通讯作者:
Dorina Avram
Study of the Dynamics and Diversity of Hematopoietic Stem Cells during Aging and Senolytic Drug Treatment Using Single Cell Transcriptomics
- DOI:
10.1182/blood-2022-170033 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:
- 作者:
Bowen Yan;Guangrong Zheng;Daohong Zhou;Olga A Guryanova - 通讯作者:
Olga A Guryanova
Olga A Guryanova的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Olga A Guryanova', 18)}}的其他基金
The role of DNMT3A mutations in clonal heterogeneity and evolution of hematopoiesis
DNMT3A 突变在克隆异质性和造血进化中的作用
- 批准号:
9977184 - 财政年份:2019
- 资助金额:
$ 34.31万 - 项目类别:
The role of DNMT3A mutations in clonal heterogeneity and evolution of hematopoiesis
DNMT3A 突变在克隆异质性和造血进化中的作用
- 批准号:
10617235 - 财政年份:2019
- 资助金额:
$ 34.31万 - 项目类别:
Biologic and therapeutic relevance of DNMT3A mutations in acute myeloid leukemia
急性髓系白血病 DNMT3A 突变的生物学和治疗相关性
- 批准号:
9320627 - 财政年份:2016
- 资助金额:
$ 34.31万 - 项目类别:
Biologic and therapeutic relevance of DNMT3A mutations in acute myeloid leukemia
急性髓系白血病 DNMT3A 突变的生物学和治疗相关性
- 批准号:
9352281 - 财政年份:2016
- 资助金额:
$ 34.31万 - 项目类别:
Biologic and therapeutic relevance of DNMT3A mutations in acute myeloid leukemia
急性髓系白血病 DNMT3A 突变的生物学和治疗相关性
- 批准号:
8716708 - 财政年份:2013
- 资助金额:
$ 34.31万 - 项目类别:
Biologic and therapeutic relevance of DNMT3A mutations in acute myeloid leukemia
急性髓系白血病 DNMT3A 突变的生物学和治疗相关性
- 批准号:
8567405 - 财政年份:2013
- 资助金额:
$ 34.31万 - 项目类别:
相似海外基金
Computing analysis of leukemic stem cell dynamics in acute myelocytic leukemia
急性粒细胞白血病白血病干细胞动力学的计算分析
- 批准号:
19K08356 - 财政年份:2019
- 资助金额:
$ 34.31万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Generation of immunotoxins with super-targeting mAb in the acute myelocytic leukemia
在急性髓细胞白血病中使用超靶向单克隆抗体产生免疫毒素
- 批准号:
23501309 - 财政年份:2011
- 资助金额:
$ 34.31万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
- 批准号:
3556971 - 财政年份:1980
- 资助金额:
$ 34.31万 - 项目类别:
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
- 批准号:
3556968 - 财政年份:1980
- 资助金额:
$ 34.31万 - 项目类别:
ERADICATION OF ACUTE MYELOCYTIC LEUKEMIA CELLS BY MAB THERAPY
通过 MAB 疗法根除急性粒细胞白血病细胞
- 批准号:
3889304 - 财政年份:
- 资助金额:
$ 34.31万 - 项目类别:














{{item.name}}会员




